POLA1 and lung carcinoma: By performing drug sensitivity tests and sequencing the DNA of human lung cancer cells for the SNP sites of interest, we were able to monitor whether the presence of POLA + 1747 GG/GA SNP could affect the response to gemcitabine treatment.